AzTrials
AzTrials

Long COVIDNCT05848401

Biosound Therapy as a Treatment for Long COVID Patients

A study testing Biosound Therapy System in people with Long COVID, run by Anxiety Relief Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID. Read more about this study

Who is it for?
Ages 20 to 65 years
Conditions the study is for
Long COVID
What is being tested?
Biosound Therapy System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
1 siteUnited States
Study dates
29 Apr 2021to 19 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • experiencing at least three symptoms that began or were intensified due to COVID
  • able to provide documentation of a COVID-19 test older than 30 days.
  • 20-65 years old.

Who cannot join

  • abusing alcohol or drugs
  • having a pacemaker or any other implanted devices
  • pregnancy
  • history of the following conditions: blood clots, schizophrenia, seizures, recent head injury, and any acute physical injury

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The Anxiety Relief Center

    Fishers, Indiana, 46038

Other trials in United States

About this study

Official title: Biosound Therapy as a Treatment for Long COVID Patients: A Randomized Pilot Trial

This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID.

The goal of this clinical trial is to learn about Biosound Therapy System's impact on long COVID symptoms. The main questions it aims to answer are:

Read more
  • How does Biosound Therapy impact long COVID symptoms?
  • Is the protocol for this trial feasible for a future full-scale Randomized Controlled Trial?

Participants with long COVID symptoms will be assigned to a control group and treatment group. The control group will receive no treatment. The treatment group will have 8 sessions of Biosound Therapy. Researchers will compare the treatment and control group to see if there's a difference in long COVID symptoms.

Read the detailed description

Investigators will recruit participants through social media and word of mouth. They will also share the study information with practitioners, businesses, organizations, research departments, universities, and the community. Participants will email or call The Anxiety Relief Center to inquire about participating in the study.

Initial screening procedures will take place using the receptionist script to determine eligibility of participants. Eligible participants who agree to participate in the study will then be asked to come into the office for an intake at a time convenient for them. This appointment will include signing the consent form and the completion of initial assessments: Cambridge Brain Sciences tasks, PHQ9, GAD7, and the COVID-19 Persistent Symptom Questionnaire.

After a participant has completed the initial intake appointment, the participant will be randomly assigned to the treatment or control group using Randomizer.org, a computer-generated randomizer. Each participant will be informed if they were assigned to the treatment or control group. An investigator will schedule two Biosound Therapy sessions per week for four weeks with every participant in the treatment group.

The Biosound Therapy System (BTS) is a system that utilizes biofeedback, vibroacoustic technology, and binaural beats. Vibroacoustic Technology uses sinusoidal, low-frequency, rhythmical pulsing sound waves in conjunction with music. The BTS device does not send electricity through the body; rather, the device uses amplifiers embedded into an adjustable bed to send frequencies between 40 and 70 Hz into the body.

At the beginning of the BTS session, the participant will complete the "Biosound Technologies Pretest" questionnaire and then will be instructed to sit on the BTS platform to begin utilizing HeartMath technology that will collect data on heart rate variability (HRV). An investigator will assist the client in attaching a finger sensor around their index finger as they recline onto the platform so that they are facing a monitor positioned in front of the platform. The monitor digitally portrays the participant's HRV and allows the participant to visually see how the rate of their breath is connected to their HRV. The participant spends a few minutes trying to match their breath rate with a moving icon called a breath pacer that is shown on the monitor. The icon moves up and down at the rate of the client's target heart rate. The monitor also displays corresponding coherence levels, which refer to the stability and balance between the brain and nervous system (HeartMath Institute, 2016). The coherence levels are color coordinated with the levels of low, medium, and high. A high coherence level signifies high stability, balance, and regulation, whereas a low coherence level signifies instability, imbalance, and dysregulation. A person with a high coherence level can operate with high efficiency. Once the participant improves their coherence level and HRV (about 5-10 minutes), an investigator will remove the finger sensor and instruct the participant to put on headphones.

Then, an investigator will begin a playlist that includes music with binaural beats that is synchronized with sound massage. Once the playlist has begun, an investigator will turn off the lights and exit the room until the playlist is finished. The session ends with video content. Each participant will be given an identical playlist for each session. At the end of the session, the participant will complete the "Biosound Technologies Posttest" questionnaire to assess the perceived effects of the session.

All collected data will be deidentified and stored in a HIPAA compliant electronic medical record system called Therapy Appointment. After a participant in the treatment group has completed their treatment sessions, they will complete the same assessments given at intake. After the assessments are completed, an investigator will ask 2 open-ended questions and then will record a summary of their answers.

While Biosound Therapy rarely causes side effects, some people may experience dizziness or discomfort. While adverse reactions are rarely reported, a decreased sense of anxiety can feel unfamiliar to people who are used to a state of physiological increased awareness. As stated above, the BTS is a wellness device that was designed to provide relief and side effects are rarely reported. All participants will be told that they can stop treatment at any time during the session by leaving the treatment room. An investigator will be in close proximity to the treatment room at all times to provide any needed assistance during participants' sessions. Snacks, water, guidance and emotional support will be available to participants should they experience any side effects. Additionally, HRV allows subjects an opportunity to see a balanced and healthy state and can help center a client who may be feeling dizzy after sound massage. The investigators will record any adverse side effects reported by the participants.

The process measures of recruitment and retention rates, open-ended interview responses, and participant characteristics will be summarized using descriptive statistics. Due to the small sample size, the Wilcoxon signed-rank test will be used to determine changes in the variables for the intervention and control group.

Conditions
Long COVID
Being tested
Biosound Therapy System
Keywords
long COVID, long haulers, post COVID syndrome, vibroacoustic therapy, biofeedback
Medical subject headings
Post-Acute COVID-19 Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Biosound Therapy SystemDevice

    Also called vibroacoustic therapy, biofeedback, binaural beats

    Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.

Study groups in NCT05848401
Study groupRoleWhat they receive
Treatment GroupExperimentalThe treatment group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The principal investigator will schedule two Biosound Therapy sessions per week for four weeks for all treatment group participants. The treatment sessions will not occur on consecutive days. All participants in the treatment group will listen to identical playlists. At the beginning of the BTS session, the participant will complete a session of HeartMath biofeedback. Next, the participant will receive approximately 30-40 minutes of music containing binaural beats synchronized with sound massage.The session will finish with gratitude-based video content.
Receives: Device: Biosound Therapy System
Control GroupNo interventionThe control group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. Control group participants were given a complimentary Biosound Therapy session and a ten dollar gift card upon completion of their final assessments.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Patient Health Questionnaire (PHQ-9)

    9-item questionnaire assessing for Major Depressive Disorder

    Measured: 4 weeks

  2. Generalized Anxiety Disorder 7-item scale (GAD-7)

    7-item questionnaire assessing for generalized anxiety disorder

    Measured: 4 weeks

  3. Cambridge Brain Sciences (CBS) tasks

    The CBS tasks measure reasoning, short-term memory, and verbal ability through 12 online tasks simulating puzzles or video games.

    Measured: 4 weeks

  4. COVID-19 Persistent Symptom Questionnaire.

    The authors developed The COVID-19 Persistent Symptom Questionnaire to measure common persistent COVID-19 symptoms at their worst over the last week on a scale of 0-3.

    Measured: 4 weeks

Secondary outcomes (3)
  1. Recruitment Rate

    Recruiting individuals with long COVID symptoms into a trial of the Biosound Therapy System

    Measured: Through study completion, an average of 1 year

  2. Retention Rate

    Retaining participants for a 4 week trial for the proposed battery of assessments. Retention rate (%) of participants enrolled into the trial who completed the 4 week protocol.

    Measured: 4 weeks

  3. Open-ended questions to participants about their experience

    Participants will be asked, "1. Can you describe your experience receiving BTS in this study? 2. How did you perceive this treatment helping or not helping your symptoms?"

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2023
  2. Study start29 Apr 2021
  3. Primary completion5 Jan 2022
  4. Study completion19 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05848401
Sponsor's protocol ID
21-ANXI-101
Status last verified
May 2023
First submitted
5 May 2023
Last updated
8 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Any researchers who are interested in replicating the study or using the de-identified IPD can contact the principal investigator for a copy of the data set.

Questions about this trial

What is this clinical trial studying?

A study testing Biosound Therapy System in people with Long COVID, run by Anxiety Relief Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Patient Health Questionnaire (PHQ-9) (time frame: 4 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in